Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1388320/000121390022015208/f10k2021_actiniumpharma.htm
SEC Filings
ATNM Annual Reports
ATNM Quarterly Reports
10-Q Quarterly Report May 2023
10-Q Quarterly Report November 2022
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report July 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report October 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report June 2020
10-Q Quarterly Report May 2023
10-Q Quarterly Report November 2022
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report July 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report October 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report June 2020
ATNM Corporate News
Regulated Disclosure March 2023
Financial Exhibit
Regulated Disclosure February 2023
Event for Officers
Financial Exhibit
Vote of Security Holders December 2022
Other Events December 2022
Financial Exhibit
Regulated Disclosure October 2022
Financial Exhibit
New Agreement June 2022
New Agreement April 2022
Event for Officers
Financial Exhibit
Vote of Security Holders November 2021
Event for Officers
Financial Exhibit
Regulated Disclosure September 2021
Event for Officers
Financial Exhibit
Vote of Security Holders November 2020
Regulated Disclosure
March 2023
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
February 2023
Event for Officers
Financial Exhibit
Vote of Security Holders
Financial Exhibit
Vote of Security Holders
December 2022
Other Events
December 2022
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
October 2022
Financial Exhibit
New Agreement
New Agreement
June 2022
New Agreement
April 2022
Event for Officers
Financial Exhibit
Vote of Security Holders
Financial Exhibit
Vote of Security Holders
November 2021
Event for Officers
Financial Exhibit
Regulated Disclosure
Financial Exhibit
Regulated Disclosure
September 2021
Event for Officers
Financial Exhibit
Vote of Security Holders
Financial Exhibit
Vote of Security Holders
November 2020
Last10K.com | 10-K Annual Report Fri Mar 25 2022
Document And Entity Information - USD ($) | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2021 | Mar. 25, 2022 | Jun. 30, 2021 | |
| Document Information Line Items | |||
| Entity Registrant Name | ACTINIUM PHARMACEUTICALS, INC. | ||
| Trading Symbol | ATNM | ||
| Document Type | 10-K | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Common Stock, Shares Outstanding | 22,143,974 | ||
| Entity Public Float | $ 138,622,140 | ||
| Amendment Flag | false | ||
| Entity Central Index Key | 0001388320 | ||
| Entity Current Reporting Status | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Well-known Seasoned Issuer | No | ||
| Document Period End Date | Dec. 31, 2021 | ||
| Document Fiscal Year Focus | 2021 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Entity File Number | 000-52446 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Tax Identification Number | 74-2963609 | ||
| Entity Address, Address Line One | 275 Madison Avenue, 7th Fl. | ||
| Entity Address, City or Town | New York | ||
| Entity Address, State or Province | NY | ||
| Entity Address, Postal Zip Code | 10016 | ||
| City Area Code | (646) | ||
| Local Phone Number | 677-3870 | ||
| Title of 12(b) Security | Common stock, par value $0.001 | ||
| Security Exchange Name | NYSE | ||
| Entity Interactive Data Current | Yes | ||
| Auditor Name | Marcumllp | ||
| Auditor Location | Houston,Texas | ||
| Auditor Firm ID | 688 |
View differences made from one year to another to evaluate Actinium Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Actinium Pharmaceuticals, Inc..
Assess how Actinium Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy
Actinium Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Rating
Learn More
Filter Sentiment:
Filter Category:
Filter Subcategory:
-
Other - Other Highlight
In determining whether goods or services are distinct, we evaluate certain criteria, including whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and (ii) the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the contract).
-
Financial - Expense Highlight
General and administrative expenses increased by $1.8 million to $8.1 million for the year ended December 31, 2021 compared to $6.3 million for the year ended December 31, 2020, primarily attributable to higher professional fees and consulting fees including recruitment costs, business taxes and fees, and insurance premiums for director and officer liability.
-
Other - Other Highlight
A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, which could in the future negatively affect our liquidity.
-
Other - Other Highlight
This ASU is effective January 1, 2022 and interim periods presented, although early adoption of this ASU was permitted effective January 1, 2021.
-
Financial - Shares Highlight
Specifically, the ASU eliminated the need for us to assess whether a contract on our own equity (1) permits settlement in unregistered shares, (2) whether counterparty rights rank higher than shareholder's rights, and (3) whether collateral is required.
-
Revenue - Product
To determine revenue recognition for...Read more
-
Financial - Expense
Net loss increased by $2.6...Read more
-
Other - Other
The amendments in this ASU...Read more
-
Other - Other
The amendments of ASU 2021-08...Read more
-
Other - Other
The amendments of ASU 2021-10...Read more
-
Other - Other
At contract inception, once the...Read more
-
Other - Other
These items are monitored and...Read more
-
Other - Other
Such government-imposed precautionary measures may...Read more
-
Financial - Expense
Research and development expenses increased...Read more
-
Other - Other
Such events may result in...Read more
-
Revenue - Product
The relative standalone selling price...Read more
-
Financial - Expense
Gross proceeds from this offering...Read more
-
Financial - Expense
Gross proceeds from this offering...Read more
-
Other - Other
We follow the accounting guidance...Read more
-
Other - Other
Further, the continuation and/or resurgence...Read more
-
Revenue - Product
Under ASC 606, we recognize...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parentheticals)
Consolidated Statement Of Changes In Stockholders??? Equity
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Accounting Policies, By Policy (Policies)
Commitments And Contingencies
Commitments And Contingencies (Details)
Description Of Business And Summary Of Significant Accounting Policies
Description Of Business And Summary Of Significant Accounting Policies (Details)
Description Of Business And Summary Of Significant Accounting Policies (Details) - Schedule Of Antidilutive Securities Excluded From Computation Of Diluted Net Loss Per Share
Description Of Business And Summary Of Significant Accounting Policies (Details) - Schedule Of Cash And Cash Equivalent And Restricted Cash
Description Of Business And Summary Of Significant Accounting Policies (Tables)
Equity
Equity (Details) - Schedule Of Stock Option Activity
Equity (Details) - Schedule Of Warrant Activities
Equity (Details)
Equity (Tables)
Income Taxes
Income Taxes (Details)
Income Taxes (Details) - Schedule Of Deferred Tax Assets And Liabilities
Income Taxes (Details) - Schedule Of Difference Between Income Tax Provision And U.S Federal Statutory Rates
Income Taxes (Tables)
Leases
Leases (Details) - Schedule Of Components Of Lease Expense
Leases (Details) - Schedule Of Maturities Of Lease Liabilities
Leases (Details) - Schedule Of Supplemental Cash Flow Information Related To Leases
Leases (Details) - Schedule Of Weighted Average Discount Rates
Leases (Details) - Schedule Of Weighted Average Remaining Lease Terms
Leases (Tables)
Other Revenue
Other Revenue (Details)
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (Details) - Schedule Of Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (Tables)
Property And Equipment
Property And Equipment (Details) - Schedule Of Depreciation Expense
Property And Equipment (Details) - Schedule Of Property And Equipment
Property And Equipment (Tables)
Material Contracts, Statements, Certifications & more
Actinium Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ATNM
CIK: 1388320
Form Type: 10-K Annual Report
Accession Number: 0001213900-22-015208
Submitted to the SEC: Fri Mar 25 2022 5:00:33 PM EST
Accepted by the SEC: Fri Mar 25 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/atnm/0001213900-22-015208.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...